Abstract 2186P
Background
Thymic carcinoma (TC) is a rare but highly aggressive cancer, with no standard treatment for patients who progress after platinum-containing chemotherapy.KN046 is a novel bispecific antibody that inhibits both PD-L1/PD1 and CTLA-4/CD80/CD86 pathways. We conducted this phase 2 study aiming to evaluate the efficacy and safety of KN046 in the TC patients who progressed after front-line chemotherapy.
Methods
Patients documented with histologically TC who progressed after platinum-containing chemotherapy were eligible. KN046 was injected intravenously at 5mg/kg Q2W until tumor progression or unacceptable toxicity. The primary endpoint was ORR by IRC, and secondary endpoints were DoR, PFS, OS, and safety. Response was assessed every 8 weeks. PD-L1 expression was measured using 22C3 PharmDx assay.
Results
From Dec 2020 to Dec 2022, 46 patients were enrolled into the study with a median age of 58 (range:38-69) years. There was no difference in gender distribution (male: female=25:21). 22 patients received more than one line of systemic chemotherapy. Most patients (91.3%) had stage IVB disease, ECOG PS was 0 in 10 (21.7%) and 1 in 36 (78.3%) patients, respectively. 17 patients had positve PD-L1, 25 patients had negative PD-L1 and 4 patients were unknown. The median follow-up time was 16.1 months (ranges:11.1-18.6 months). Of 38 evaluable patients, 7 achieved partial response and 17 remained stable disease, while the other 14 experienced progressive disease. The ORR was 16.3% (95%CI: 6.8%, 30.7%), the mDoR was 10.1 months (95%CI: 7.7, NE). The mPFS was 5.6 months (95%CI: 1.9, 12.8). The mOS was immature, the 18-months OS rate was 74.1% (95%CI: 54.29, 86.32). Among the PD-L1-positive patients, the ORR and PFS were numerically higher than that in PD-L1 negative or status unknown, which was 18.8% vs. 14.8% in ORR and 7.6 months vs 5.6 months in PFS. The most common TRAE of any grade include rash (39.1%), ALT increased (32.6%), AST increased (28.3%). 8 patients experienced ≥ grade 3 irAE, 7 (15.2%) patients discontinued study treatment due to TRAE, but there was no death event related with KN046.
Conclusions
KN046 demonstrated promising antitumor activity and acceptable toxicity in thymic carcinoma patients who have received at least one line of chemotherapy.
Clinical trial identification
NCT04469725.
Editorial acknowledgement
Legal entity responsible for the study
Alphamab Oncology.
Funding
Alphamab Oncology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2130P - ATTITUDE - ATTrition In longiTUDinal studiEs of cancer survivors (CS): Can we improve the experience of patients (pts)?
Presenter: Camila Chiodi
Session: Poster session 07
2131P - Real-life experiences from a late effects clinic: An investigation of health-related quality of life in Danish cancer survivors
Presenter: Lærke Tolstrup
Session: Poster session 07
2132P - Unmet needs, quality of life, and financial toxicity in survivors of lung cancer
Presenter: Josephine Feliciano
Session: Poster session 07
2133P - Sleep disorders: Evolution in time in early breast cancer (EBC)
Presenter: Blanca Cantos
Session: Poster session 07
2134P - Self-reported late effects, need for information and follow-up in long-term Hodgkin lymphoma survivors
Presenter: Lise Willumsen
Session: Poster session 07
2135P - Impact of geriatric assessment (GA) and geriatric 8(G8)-based targeted interventions on the quality of life (QoL) in older Asian adults with cancer
Presenter: Jia Li Low
Session: Poster session 07
2136P - Prostate cancer supportive care (PCSC) program for patients and partners: A model for meeting an unmet need for PC patients
Presenter: Celestia Higano
Session: Poster session 07
2137P - Impact of supportive care on the quality of life (QoL) of hospitalized cancer patients (pts)
Presenter: Judit Sanz Beltran
Session: Poster session 07
2138P - Time toxicity of palliative chemotherapy in a geriatric oncology population
Presenter: Christopher Cronin
Session: Poster session 07
2139P - Quality of life in adult cancer survivors (QLACS) in Spain: Study of its clinical characteristics and use of social media for oncological information
Presenter: Maria Cornide Santos
Session: Poster session 07